Project description
Fellowship to study prescription drugs during pregnancy
What are the risks and benefits of prescribed drug use during pregnancy? This question will be investigated by the newly established ‘International Pregnancy Safety Study’ (InPreSS) consortium, which brings together research groups with access to healthcare databases and demonstrated ability to study the safety of medications in pregnancy. This EU-funded project offers a global fellowship position at InPreSS. The fellow will be based at the Centre for Pharmacoepidemiology, Karolinska Institute (CPE/KI) in Sweden, with collaborators including researchers in all five Nordic countries and the Harvard School of Public Health (HSPH) in the US. The fellow will receive the highest quality support, facilitating long-term partnerships, training and contributing to the field with studies that impact clinical practice and guidelines for pregnant women.
Objective
This is a proposal for a global fellowship position within the International Pregnancy Safety Study (InPreSS), a recently established international collaboration based at the Centre for Pharmacoepidemiology, Karolinska Institute (CPE/KI), Sweden, between researchers in all five Nordic countries and the Harvard School of Public Health (HSPH), USA. The majority of pregnant women take prescription drugs but there is limited evidence of their efficacy and safety. InPreSS aims to conduct exceedingly important research into the risk and benefits of prescribed drug use during pregnancy. The overarching objective of this fellowship is to provide advanced training in reproductive pharmacoepidemiology while creating a platform from which to launch an independent academic career in the EU. Three specific aims are to: 1) investigate the efficacy/safety of prescribed drugs used treatment of diabetes during pregnancy; 2) to trial the InPreSS international research model to evaluate short- and long-term infant and maternal health outcomes following use of prescribed drugs for chronic disease treatment during pregnancy using an unparalleled global resources of over 5 million pregnancies; 3) provide experience and mentorship at HSPH to design and deliver courses in pharmacoepidemiology in Sweden. Aims will be achieved via an 18-month out-going phase at HSPH where the Fellow will use the latest methodologies in pharmacoepidemiology to analyze a dataset comprised of US health insurance data, and a 12-month return-phase at CPE/KI where the results will be combined using meta-regression techniques. The Fellow will receive the highest quality support while facilitating long-term partnerships, training the next generation of researchers, and contributing to the field with studies that will directly impact clinical practice and guidelines for pregnant women.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences public health
- medical and health sciences clinical medicine endocrinology diabetes
- medical and health sciences clinical medicine obstetrics
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2018
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
171 77 STOCKHOLM
Sweden
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.